A detailed history of Dafna Capital Management LLC transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Dafna Capital Management LLC holds 341,064 shares of ADAP stock, worth $197,817. This represents 0.08% of its overall portfolio holdings.

Number of Shares
341,064
Previous 341,064 -0.0%
Holding current value
$197,817
Previous $334,000 2.99%
% of portfolio
0.08%
Previous 0.09%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.7 - $1.75 $7,000 - $17,500
-10,000 Reduced 2.85%
341,064 $538,000
Q1 2022

May 16, 2022

BUY
$1.73 - $4.06 $371,600 - $872,079
214,798 Added 157.63%
351,064 $723,000
Q4 2021

Feb 14, 2022

BUY
$3.5 - $5.68 $476,931 - $773,990
136,266 New
136,266 $511,000

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $94.8M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Dafna Capital Management LLC Portfolio

Follow Dafna Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.